Croasdale has more than 20 years of commercial and financial experience in the medtech industry. He will oversee the tissue reconstruction company’s growth strategy and corporate development.
“We are delighted to welcome Chad to RTI. His extensive experience in driving commercial success will be invaluable as we continue to establish ourselves as the CDMO partner of choice in regenerative medicine, leveraging our unique portfolio of xenograft and allograft biomaterials to improve patient outcomes,” President and CEO Olivier Visa said in a news release.
Prior to joining the Alachua, Florida-based company, Croasdale was president and chief commercial officer of 270Surgical. He also previously spent more than 18 years at Stryker, serving in roles of increasing responsibility, eventually becoming the VP and general manager of Stryker Communications, Endoscopy. There, he oversaw the communications business unit and drove commercial, sales and R&D operations.
“I am excited to join RTI Surgical, a company with a strong reputation for its commitment to quality, innovation and patients, and a clear strategy for growth. I look forward to working with the team and our OEM partners to develop biomaterials and expand our reach to even more patients,” Croasdale said.
